Clinical trial software for biotech accelerators and incubators

Accelerators and incubators are good at helping a founding team get to a clinical hypothesis. The wall comes a few months later, when the first protocol is signed off and someone has to decide how data will actually be collected. The options a startup sees are unattractive. A spreadsheet or a general survey tool is fast and free, but it has no audit trail, no real access control and no way to answer an inspector who asks who changed a value and why. A big enterprise EDC has the controls, but arrives with a sales cycle, an implementation project and a contract sized for a company ten times larger.

Multiply that by every company in your cohort and the cost becomes a program-level problem. Mentors spend office hours explaining what an EDC is. Founders burn weeks on vendor calls instead of on recruitment. Some choose a tool that cannot carry them to a pivotal study and have to migrate mid-trial, which is the most expensive time to change anything. A single, sensible default that every portfolio company can start with removes a large part of that friction.

Capture was built for exactly this profile: a small team, no IT staff, a limited budget, and a need for Part 11-aligned controls without an enterprise contract. See clinical trial software for startup biotech and platforms for seed-stage biotech for the founder's view of the same decision.

A portfolio company that signs up gets the whole platform, not a cut-down starter tier. The eCRF builder supports skip logic, edit checks that raise an automatic query when a site enters an out-of-range value, calculated fields such as BMI or eGFR, and a draft-to-approved lifecycle that locks forms before live use. ePRO and eConsent sit in the same system, so participant questionnaires and consent documents share one audit trail with the clinical data.

For a founder who has a protocol but not a data manager, the AI study builder is the shortcut worth showing in a cohort workshop. Upload the protocol as PDF or DOCX and it drafts the visit schedule and forms; nothing is saved until a person reviews it. It does not replace a data management plan, but it turns a blank page into a first draft in minutes. Pair it with the data management plan template and the protocol template so the supporting documents exist before the first visit.

Multi-site reach matters even for small startups, because first-in-human and proof-of-concept studies often involve two or three sites. Site coordinators get their own portal, participants are numbered per site, and exports can be filtered by site. Role-based access keeps personal identifiers with site staff while researchers see coded IDs.

Investors, partners and regulators all eventually ask the same questions about a startup's trial data: who can see it, who can change it, and can you prove what changed. The honest answer from Capture's side is specific. The audit trail is field-level, capturing the timestamp, user, old value, new value and reason for change. It is append-only at the database layer and exportable. Electronic signatures re-authenticate the signer and link to the exact document content. Access is role-based, and blinded roles never receive treatment-arm values.

It is just as important to be straight about what software alone cannot do. 21 CFR Part 11 compliance is a shared responsibility: the platform provides the controls, and the sponsor is responsible for validated, documented use of them. That means procedures, training records, a validation approach proportionate to the study, and a sponsor who can show how the system is used. The computer system validation guide and the Part 11 compliance checklist set out that sponsor-side work, and the security page lists the controls we describe publicly. An accelerator can add real value by making these documents part of its curriculum.

Capture does not claim certifications it does not hold, so ask any vendor, including us, for exactly the documentation your portfolio companies will need to show their own sponsors and auditors.

Capture is a good default for portfolio companies running early and mid-stage trials with small to mid-sized teams: first-in-human studies, proof-of-concept cohorts, device and digital health studies, and later-phase studies run by teams that want a modern, self-serve system. It is not the right tool for every need. A company that depends on complex multi-depot drug supply logistics, a specialist imaging core lab or a dedicated pharmacovigilance safety database will use specialist systems for those jobs alongside the EDC. If a company already has a full-service CRO that mandates its own EDC, the CRO's system will usually win for that study.

For founders weighing whether to run lean or hire a vendor, how to run a clinical trial without a CRO and build vs buy EDC cover the trade-offs. For the cost picture, how much a clinical trial costs gives broad industry ranges, and clinical trial software without enterprise pricing explains the pay-when-live model.